Cargando…

Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age

Vaccination offers the best way to prevent invasive meningococcal disease (IMD). As demonstrated in countries with national immunization programs (NIPs) against IMD, meningococcal conjugate vaccines have contributed to significant declines in incidence. Since some meningococcal vaccines are associat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marshall, Gary S., Pelton, Stephen I., Robertson, Corwin A., Oster, Philipp
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Meningococcal – Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746432/ https://www.ncbi.nlm.nih.gov/pubmed/35947774 http://dx.doi.org/10.1080/21645515.2022.2099142

Ejemplares similares

Real-world impact and effectiveness of MenACWY-TT
por: Villena, Rodolfo, et al.
Publicado: (2023)

Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study
por: Robertson, Corwin A., et al.
Publicado: (2023)

3. A Review of the Clinical Development of MenACWY-TT, a Quadrivalent Meningococcal Vaccine Conjugated to Tetanus Toxoid, in Adolescents
por: Peyrani, Paula, et al.
Publicado: (2020)

Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents
por: Quiambao, Beatriz P., et al.
Publicado: (2016)

Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial
por: Knuf, Markus, et al.
Publicado: (2022)

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
por: Sow, Samba O., et al.
Publicado: (2023)

Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10–25 Years of Age
por: Halperin, Scott A., et al.
Publicado: (2014)

Immunogenicity of MenACWY-CRM in Korean Military Recruits: Influence of Tetanus-Diphtheria Toxoid Vaccination on the Vaccine Response to MenACWY-CRM
por: Kim, Han Wool, et al.
Publicado: (2016)

Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2–10-year-old children: results of an open, randomised, controlled study
por: Knuf, Markus, et al.
Publicado: (2013)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study
por: van der Vliet, D., et al.
Publicado: (2021)

Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children
por: Knuf, Markus, et al.
Publicado: (2012)

Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra(®)) in the Republic of Korea, 2014–2019
por: Kim, Hee Soo, et al.
Publicado: (2021)

Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled Trial
por: Dbaibo, Ghassan, et al.
Publicado: (2013)

Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents
por: Quiambao, Beatriz P., et al.
Publicado: (2017)

1478. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS
por: Quiambao, Beatriz, et al.
Publicado: (2019)

2722 B. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS
por: Quiambao, Beatriz, et al.
Publicado: (2019)

The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: A randomized, controlled non-inferiority study
por: Dbaibo, Ghassan, et al.
Publicado: (2012)

14. Postmarketing Safety Experience With MenACWY-TT
por: Serra, Lidia, et al.
Publicado: (2021)

Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults
por: Díez-Domingo, Javier, et al.
Publicado: (2021)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study
por: Vesikari, Timo, et al.
Publicado: (2020)

Preclinical development of the quadrivalent meningococcal (ACYW) tetanus toxoid conjugate vaccine, MenQuadfi®
por: Kensinger, Richard, et al.
Publicado: (2022)

Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review
por: Abitbol, Véronique, et al.
Publicado: (2023)

2456. Immunogenicity and Safety of a MenACWY-CRM Booster Dose 4–6 Years After Primary Quadrivalent Meningococcal Conjugate Vaccination in Healthy US Adolescents and Adults
por: Tipton, Mary, et al.
Publicado: (2018)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study
por: Kirstein, Judith, et al.
Publicado: (2020)

Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study
por: Áñez, Germán, et al.
Publicado: (2020)

Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study
por: Piazza, Franco M., et al.
Publicado: (2021)

The investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults
por: Reyes, Mari Rose Aplasca-De Los, et al.
Publicado: (2012)

Meningococcal disease within the Gulf Cooperation Council Countries
por: Al Awaidy, Salah, et al.
Publicado: (2023)

Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study
por: Zambrano, Betzana, et al.
Publicado: (2023)

Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine
por: Vesikari, Timo, et al.
Publicado: (2015)

Pandemic’s influence on parents’ attitudes and behaviors toward meningococcal vaccination
por: Tan, Litjen (L.J), et al.
Publicado: (2023)

Review of the epidemiology, diagnosis and management of invasive meningococcal disease in Vietnam
por: The Nguyen, Phung Nguyen, et al.
Publicado: (2023)

Changing patterns of invasive meningococcal disease and future immunization strategies
por: Taha, Muhamed-Kheir, et al.
Publicado: (2023)

Meningococcal burden of disease in Argentina: 10 years epidemiologic review
por: Neyro, Silvina, et al.
Publicado: (2023)

Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY-TT Vaccine: A Review
por: Presa, Jessica, et al.
Publicado: (2019)

Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults
por: Presa, Jessica, et al.
Publicado: (2023)

Tolerability of MenACWY-TT vaccination in adolescents in the Netherlands; a cross-sectional study
por: Kemmeren, J. M., et al.
Publicado: (2021)

Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines
por: Serra, Lidia, et al.
Publicado: (2021)

Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine
por: Watle, Sara Viksmoen, et al.
Publicado: (2021)

Meningococcal serogroup B vaccination series initiation in the United States: A real-world claims data analysis
por: Packnett, Elizabeth R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nme5nqg03ntf8c6bed463osf1o